ADMA
ADMA Biologics, Inc. NASDAQ Listed Oct 17, 2013$8.47
Mkt Cap $2.0B
52w Low $7.21
8.1% of range
52w High $22.73
50d MA $12.19
200d MA $15.73
P/E (TTM)
17.0x
EV/EBITDA
21.9x
P/B
5.2x
Debt/Equity
0.2x
ROE
30.8%
P/FCF
156.2x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$12.19
200d MA
$15.73
Avg Volume
5.8M
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
465 State Route 17 · Ramsey, NJ 07446 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.19 | 0.19 | -1.7% | 10.08 | -25.3% | -16.0% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.18 | 0.20 | +8.1% | 15.68 | +3.6% | -3.2% | +2.6% | +6.5% | -1.2% | +1.0% | — |
| Nov 5, 2025 | AMC | 0.16 | 0.16 | +0.0% | 15.37 | -3.1% | -8.7% | +3.5% | +1.3% | +9.0% | +2.7% | — |
| Aug 6, 2025 | AMC | 0.14 | 0.15 | +7.1% | 18.54 | -14.5% | -9.7% | -1.4% | -0.8% | +2.3% | +2.6% | — |
| May 7, 2025 | AMC | 0.16 | 0.14 | -12.5% | 23.61 | -3.7% | -10.2% | -5.8% | +2.4% | -2.8% | -2.1% | — |
| Mar 3, 2025 | AMC | 0.15 | 0.14 | -6.7% | 15.83 | -5.9% | +7.5% | +3.9% | -4.4% | +0.7% | -2.4% | — |
| Nov 7, 2024 | AMC | 0.13 | 0.15 | +15.4% | 19.72 | +5.3% | +14.7% | -0.6% | -3.1% | -1.4% | -5.9% | — |
| Aug 8, 2024 | AMC | 0.08 | 0.13 | +62.5% | 12.19 | +23.9% | +30.9% | +3.1% | +5.0% | +1.7% | +0.1% | — |
| May 9, 2024 | AMC | 0.06 | 0.08 | +33.3% | 6.93 | +18.3% | +27.1% | -0.2% | +4.2% | -0.7% | -0.4% | — |
| Feb 28, 2024 | AMC | -0.01 | 0.04 | +420.0% | 5.38 | +0.0% | -0.4% | +3.0% | +3.6% | +1.4% | +5.5% | — |
| Nov 8, 2023 | AMC | 0.00 | 0.01 | +233.3% | 3.62 | +10.5% | +5.8% | -1.6% | -0.8% | +3.5% | -1.8% | — |
| Aug 9, 2023 | AMC | -0.02 | -0.02 | -19.8% | 4.06 | +3.4% | +6.2% | +3.9% | +2.9% | -1.5% | -2.2% | — |
| May 10, 2023 | AMC | -0.05 | -0.03 | +40.0% | 3.57 | +9.2% | +10.9% | +6.6% | -0.7% | -2.6% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Canaccord Genuity | Initiates | Buy | $21 | $10.88 | $11.12 | +2.2% | -0.9% | +1.6% | +1.2% | +1.6% | -2.9% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $9.70 | $9.74 | +0.4% | +7.0% | +1.1% | +1.5% | +0.8% | +2.5% |
| Mar 26 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $9.63 | $8.98 | -6.7% | -13.9% | +11.6% | -1.1% | -1.5% | +1.1% |
| May 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $23.61 | $22.73 | -3.7% | -10.2% | -5.8% | +2.4% | -2.8% | -2.1% |
| Mar 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.83 | $14.90 | -5.9% | +7.5% | +3.9% | -4.4% | +0.7% | -2.4% |
| Nov 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $19.72 | $20.76 | +5.3% | +14.7% | -0.6% | -3.1% | -1.4% | -5.9% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.72 | $20.76 | +5.3% | +14.7% | -0.6% | -3.1% | -1.4% | -5.9% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.15 | $17.03 | -0.7% | -4.5% | +1.3% | -0.8% | -1.9% | -2.1% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.74 | $19.87 | +0.7% | +1.2% | +0.3% | -3.7% | +1.0% | -0.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.96 | $16.02 | +0.4% | +3.1% | +5.0% | +1.7% | +0.1% | -0.2% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.19 | $15.10 | +23.9% | +30.9% | +3.1% | +5.0% | +1.7% | +0.1% |
| Jul 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.64 | $11.81 | +1.5% | +2.7% | +0.3% | +2.6% | +3.8% | +4.8% |
| Jun 20 | Mizuho | Maintains | Buy → Buy | — | $10.62 | $10.82 | +1.9% | +0.8% | +2.7% | +0.1% | +0.0% | -1.5% |
| May 10 | Mizuho | Maintains | Buy → Buy | — | $6.93 | $8.20 | +18.3% | +27.1% | -0.2% | +4.2% | -0.7% | -0.4% |
| May 10 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $6.93 | $8.20 | +18.3% | +27.1% | -0.2% | +4.2% | -0.7% | -0.4% |
| May 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.93 | $8.20 | +18.3% | +27.1% | -0.2% | +4.2% | -0.7% | -0.4% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.93 | $8.20 | +18.3% | +27.1% | -0.2% | +4.2% | -0.7% | -0.4% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.39 | $6.49 | +1.6% | +1.7% | +3.7% | -2.1% | -0.9% | -1.5% |
| Mar 1 | Mizuho | Maintains | Buy → Buy | — | $5.36 | $5.38 | +0.4% | +3.0% | +3.6% | +1.4% | +5.5% | +0.7% |
| Feb 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.38 | $5.38 | +0.0% | -0.4% | +3.0% | +3.6% | +1.4% | +5.5% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.38 | $5.38 | +0.0% | -0.4% | +3.0% | +3.6% | +1.4% | +5.5% |
| Jan 22 | Mizuho | Maintains | Buy → Buy | — | $5.01 | $5.00 | -0.2% | +5.6% | -0.4% | -4.2% | +0.6% | +0.2% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.81 | $4.79 | -0.4% | +5.4% | -2.2% | -0.4% | +1.0% | -1.2% |
| Dec 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.14 | $4.19 | +1.2% | +1.9% | -3.1% | +1.0% | +2.7% | +2.8% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.81 | $3.84 | +0.8% | +4.2% | +1.5% | -2.2% | +0.3% | +0.3% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.20 | +3.4% | +6.2% | +3.9% | +2.9% | -1.5% | -2.2% |
| Aug 10 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $4.06 | $4.20 | +3.4% | +6.2% | +3.9% | +2.9% | -1.5% | -2.2% |
| Aug 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.06 | $4.20 | +3.4% | +6.2% | +3.9% | +2.9% | -1.5% | -2.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.32 | $3.37 | +1.5% | +0.0% | -3.3% | +1.9% | -3.4% | +4.7% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $3.89 | +0.8% | -1.8% | -5.0% | -0.6% | +2.2% | -1.9% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $3.94 | +1.5% | -0.3% | -5.7% | -1.4% | +0.8% | -3.3% |
| Nov 10 | Mizuho | Maintains | Buy → Buy | — | $2.47 | $2.77 | +12.1% | +27.5% | +3.8% | +1.2% | -2.1% | -2.5% |
| Oct 13 | Mizuho | Maintains | Buy → Buy | — | $2.54 | $2.55 | +0.4% | +6.3% | -3.0% | +2.7% | +1.9% | -5.5% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.16 | -0.5% | +0.9% | -2.7% | +1.4% | +0.5% | -1.4% |
| Nov 11 | Raymond James | Upgrade | Outperform → Strong Buy | — | $1.40 | $1.51 | +7.9% | +13.6% | +4.4% | -6.6% | +0.0% | -3.2% |
| Nov 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.38 | $1.45 | +5.1% | +2.9% | -1.4% | +13.6% | +4.4% | -6.6% |
| Oct 26 | Raymond James | Maintains | Outperform → Outperform | — | $1.23 | $1.26 | +2.4% | +9.8% | +0.0% | -0.7% | -3.7% | +4.7% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.53 | $1.55 | +1.3% | -1.3% | -1.3% | -3.4% | -7.6% | -3.8% |
| Jul 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.57 | +1.3% | -2.6% | -2.0% | -3.4% | +4.9% | -4.0% |
| Mar 26 | Raymond James | Maintains | Outperform → Outperform | — | $2.05 | $1.96 | -4.4% | -11.7% | -7.7% | +2.4% | +2.9% | +4.0% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $2.02 | +3.6% | +8.2% | +1.9% | -3.3% | +3.4% | -0.5% |
| Oct 1 | Raymond James | Maintains | Outperform → Outperform | — | $2.39 | $2.41 | +0.8% | -6.7% | +11.7% | +0.0% | -2.8% | +5.8% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.20 | $2.90 | -9.4% | -18.1% | -7.6% | +10.3% | -4.5% | -2.4% |
| Mar 16 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.16 | $1.84 | -14.8% | -16.7% | +11.1% | -25.0% | +40.7% | +6.6% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $1.84 | -14.8% | -16.7% | +11.1% | -25.0% | +40.7% | +6.6% |
| Jun 4 | Jefferies | Maintains | Buy → Buy | — | $4.20 | $4.31 | +2.6% | +4.5% | -1.8% | -12.5% | +0.3% | -0.3% |
| Apr 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.07 | $6.26 | +53.8% | +24.3% | +1.2% | +1.4% | -2.1% | +1.2% |
| Oct 30 | H.C. Wainwright | Maintains | Buy → Buy | — | $5.03 | $5.30 | +5.4% | +6.6% | +0.2% | +3.0% | +1.6% | -0.4% |
| Oct 12 | Raymond James | Maintains | Outperform → Outperform | — | $5.56 | $5.58 | +0.4% | -5.9% | +2.5% | -1.3% | +1.5% | +3.9% |
| Jul 30 | Chardan Capital | Maintains | Buy → Buy | — | $6.09 | $6.58 | +8.0% | +3.1% | +3.8% | -1.8% | -2.3% | -0.3% |
No insider trades available.
8-K · 8.01
!! High
ADMA Biologics, Inc. -- 8-K 8.01: Material Event / Announcement
ADMA Biologics received FDA approval to expand ASCENIV's label to pediatric immunocompromised patients aged 2+, potentially broadening its addressable market and revenue opportunities.
May 4
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ADMA disclosed material information via Regulation FD, suggesting the company made a public announcement; investors should monitor the complete filing details to assess implications for operations, financial performance, or strategic direction.
Mar 27
8-K · 8.01
!! High
ADMA Biologics, Inc. -- 8-K 8.01: Material Event / Announcement
ADMA Biologics disclosed a material announcement in its press release, though the specific details require review of the exhibit for investor impact assessment.
Mar 2
8-K · 5.02
!!! Very High
ADMA Biologics, Inc. -- 8-K 5.02: Executive Change
ADMA Biologics appointed Mr. Kohler as Chief Financial Officer while director Tade resigned, signaling potential operational restructuring that investors should monitor for impact on financial management and governance.
Feb 25
Data updated apr 24, 2026 10:57am
· Source: massive.com